Nektar TherapeuticsNKTR
13F holders, Q1 2026 (March 31)8holders
3new positions
3sold out
$71.73avg. 13F price*
At the end of Q1 2026, 8 institutions reported holding Nektar Therapeutics (NKTR) in their 13F filings, unchanged from Q4 2025. 3 opened new positions and 3 sold out. The largest holders were EverSource Wealth Advisors, LLC ($8K), Hollencrest Capital Management ($4K) and Fortitude Family Office, LLC ($504).
- Company
- Nektar Therapeutics
- CUSIP
- 640268108
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $5K |
| Exits | 3 | $276K |
All 13F filers, Q4 2025 → Q1 2026: 67 shares bought and 6,677 shares sold, net −6,610 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| EverSource Wealth Advisors, LLC | 0.00% | Add +0.9% | 111 | $8K |
| Hollencrest Capital Management | 0.00% | New | 60 | $4K |
| Fortitude Family Office, LLC | 0.00% | Reduce -66.7% | 7 | $504 |
| Twin Peaks Wealth Advisors, LLC | 0.00% | New | 5 | $384 |
| Farther Finance Advisors, LLC | 0.00% | Reduce -99.3% | 1 | $76 |
| Root Financial Partners, LLC | 0.00% | New | 1 | $72 |
| LRI Investments, LLC | 0.00% | No change | 1 | $72 |
| Huntington National Bank | 0.00% | No change | 1 | $1 |
"% of holder's portfolio" is NKTR's weight in each manager's 13F, not the share of Nektar Therapeutics the manager owns.